{"disease":{"id":"bacterial-infections","name":"bacterial infections"},"drugs":{"marketed":[{"drug_id":"cefiderocol","indication_name":"Gram-Negative Bacterial Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetroja","generic_name":"CEFIDEROCOL","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":"300","mechanism":"Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death."},{"drug_id":"delafloxacin","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baxdela","generic_name":"DELAFLOXACIN","company_name":"Melinta","drug_phase":"marketed","molecular_target":"","drug_class":"Fluoroquinolone Antibacterial","quality_score":65,"revenue":null,"mechanism":"Baxdela works by blocking bacterial enzymes that replicate DNA."},{"drug_id":"bacitracin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"BACITRACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"bacitracin","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"sulfadiazine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ceftaroline","indication_name":"Acute bacterial skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftaroline Fosamil","generic_name":"CEFTAROLINE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins."},{"drug_id":"chlortetracycline","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aureomycin","generic_name":"CHLORTETRACYCLINE","company_name":"","drug_phase":"marketed","molecular_target":"Protein-arginine deiminase type-4","drug_class":"chlortetracycline","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"neomycin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"polymyxin-b","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"silvadene","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silvadene","generic_name":"Silver Sulfadiazine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"bacterial cell membrane and cell wall","drug_class":"sulfonamide antimicrobial","quality_score":65,"revenue":null,"mechanism":"Silver sulfadiazine acts on bacterial cell membrane and cell wall to produce bactericidal effect."},{"drug_id":"cortisol","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"omadacycline-tosylate","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuzyra","generic_name":"OMADACYCLINE TOSYLATE","company_name":"Paratek Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":56,"revenue":null,"mechanism":"Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"pramocaine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05353634","title":"Metagenomic Sequencing in Clinical Infectious Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2022097,"lead_sponsor_name":"Liaocheng People's Hospital","has_results":false},{"nct_id":"NCT06377592","title":"Development and Accuracy Evaluation of Gram Staining Analysis AI","phase":"","overall_status":"RECRUITING","enrollment_count":18000,"lead_sponsor_name":"GramEye","has_results":false},{"nct_id":"NCT06620341","title":"A Cluster Randomized Controlled Trial to Compare the Rate of Antibiotic Infusion","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":11900,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04633603","title":"LázBarát™ (FeverFriend™) Projekt: Attitude Toward Fever and Its Change in the Healthcare System","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of Pecs","has_results":false},{"nct_id":"NCT03397433","title":"ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record","phase":"NA","overall_status":"COMPLETED","enrollment_count":9673,"lead_sponsor_name":"Endeavor Health","has_results":false},{"nct_id":"NCT03646227","title":"Multi-Drug Resistant Organism Network","phase":"","overall_status":"COMPLETED","enrollment_count":6496,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04841369","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3420,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT01340937","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2808,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03767374","title":"Risk-factors for Multidrug-resistant Bacteria Colonization Among Patients at High Risk of STIs","phase":"","overall_status":"COMPLETED","enrollment_count":2186,"lead_sponsor_name":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","has_results":false},{"nct_id":"NCT03925480","title":"Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2110,"lead_sponsor_name":"Murdoch Childrens Research Institute","has_results":false},{"nct_id":"NCT05259683","title":"Febrile Infant Diagnostic Assessment and Outcome Study","phase":"","overall_status":"COMPLETED","enrollment_count":2076,"lead_sponsor_name":"Queen's University, Belfast","has_results":false},{"nct_id":"NCT05336851","title":"Emergency PWAS in Respiratory Infectious Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06419426","title":"Prospective Study on Febrile Batteries in Pediatric Oncohaematological Patients (SuBiTo)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Associazione Italiana Ematologia Oncologia Pediatrica","has_results":false},{"nct_id":"NCT05641025","title":"Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis","phase":"","overall_status":"COMPLETED","enrollment_count":1774,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT05722184","title":"Diagnostic Evaluation Study of the BactInsight Blood Culture System in West-Africa","phase":"","overall_status":"COMPLETED","enrollment_count":1724,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT01337167","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1473,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07111793","title":"Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics","phase":"NA","overall_status":"RECRUITING","enrollment_count":1401,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT01480258","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1315,"lead_sponsor_name":"MCM Vaccines B.V.","has_results":true},{"nct_id":"NCT01341639","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"MCM Vaccines B.V.","has_results":true},{"nct_id":"NCT06634940","title":"International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT03475472","title":"Direct Molecular Characterization of Bacteria From ICU and From the REHAB","phase":"","overall_status":"COMPLETED","enrollment_count":971,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT04688216","title":"Developing a Risk Assessment System of Multidrug-resistant Organisms Infection","phase":"","overall_status":"COMPLETED","enrollment_count":917,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03941951","title":"Study to Optimize the Use of New Antibiotics","phase":"NA","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT03761043","title":"Nurse Promotion of IV to PO Antimicrobial Conversion","phase":"NA","overall_status":"COMPLETED","enrollment_count":853,"lead_sponsor_name":"Kelowna General Hospital","has_results":false},{"nct_id":"NCT02852902","title":"Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.","phase":"","overall_status":"COMPLETED","enrollment_count":820,"lead_sponsor_name":"Spanish Network for Research in Infectious Diseases","has_results":false},{"nct_id":"NCT05942157","title":"Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections","phase":"NA","overall_status":"UNKNOWN","enrollment_count":810,"lead_sponsor_name":"Singapore General Hospital","has_results":false},{"nct_id":"NCT03192072","title":"A Rapid Test for Acute Respiratory Illness","phase":"","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06995846","title":"Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic Experiment","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":700,"lead_sponsor_name":"Beijing YouAn Hospital","has_results":false},{"nct_id":"NCT03137173","title":"Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":679,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":true},{"nct_id":"NCT01170221","title":"TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":667,"lead_sponsor_name":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01421511","title":"TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":666,"lead_sponsor_name":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT07017777","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT02066402","title":"Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":598,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04196192","title":"Febrile Infants - Diagnostic Assessment and Outcome","phase":"","overall_status":"COMPLETED","enrollment_count":555,"lead_sponsor_name":"Belfast Health and Social Care Trust","has_results":false},{"nct_id":"NCT03405064","title":"Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":501,"lead_sponsor_name":"Wockhardt","has_results":false},{"nct_id":"NCT06155266","title":"Combination of Leukocyte Cell Surface Biomarkers Measured by Cytometry, to Differentiate Bacterial From Viral Infections in Emergency Department: a Multicentric Cohort for the Validation of Diagnostic Performances","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03204591","title":"Bacterial Infections in Cirrhotic Patients With Acute Severe Liver Injury","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"The Zhejiang Study Group for Organ Failure in Cirrhosis","has_results":false},{"nct_id":"NCT02848534","title":"The Value of the Neutrophil to Lymphocyte Ratio in the Diagnosis of Bacterial Infections","phase":"","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT03919032","title":"Bacterial Infections in Patients with Cirrhosis in Argentina: Clinical and Microbiological Characteristics","phase":"","overall_status":"COMPLETED","enrollment_count":472,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT05293418","title":"Incidence of Colonization by Multidrug-resistant Organisms in Mechanically Ventilated Patients With Severe COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":435,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT04777747","title":"The Role of Lactate in Viral and Bacterial Infection","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT04609384","title":"Nudging Effect of Timer on Surgical Rub","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Sygehus Lillebaelt","has_results":false},{"nct_id":"NCT07205575","title":"AI-Guided Proteomic Biomarker Panel for Differentiating Bacterial and Viral Infections in Acute Febrile Illness","phase":"","overall_status":"COMPLETED","enrollment_count":394,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT01839188","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"MCM Vaccines B.V.","has_results":true},{"nct_id":"NCT06592586","title":"A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":338,"lead_sponsor_name":"Minervax ApS","has_results":false},{"nct_id":"NCT06174519","title":"Evaluation of the Artificial Intelligence-based Prescription Support Software iAST® for the Choice of Empirical and Semi-targeted Antibiotic Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Pragmatech AI Solutions","has_results":false},{"nct_id":"NCT03159403","title":"A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Melinta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03896685","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Médecins Sans Frontières, France","has_results":false},{"nct_id":"NCT02961764","title":"Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04917380","title":"The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}